Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled ‘An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension.’ The study aims to assess the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients who have previously participated in related Phase 3 and Phase 4 studies. This research is significant as it could provide insights into the prolonged use of Bimatoprost SR, potentially impacting treatment protocols for glaucoma and ocular hypertension.
The intervention being tested is Bimatoprost SR, an intraocular implant designed to manage eye pressure in patients with glaucoma or ocular hypertension. The study also includes standard of care treatments based on the investigator’s judgment.
The study design is interventional with a non-randomized, parallel assignment model. There is no masking involved, and the primary purpose is treatment. This straightforward design allows for a clear evaluation of the treatment’s long-term effects.
The study began on March 27, 2019, with a primary completion date yet to be announced. The latest update was submitted on August 5, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
Market implications of this study update could be significant for AbbVie, as positive results may enhance investor confidence and potentially boost stock performance. The study’s outcomes could also influence the competitive landscape in the glaucoma treatment market, where innovation is key.
The study is ongoing, and further details are available on the ClinicalTrials portal.